Trans-Atlantic play

Backed by a $175 million infusion from investors, EUSA Pharma Inc. says last week's acquisition of specialty pharma company OPi S.A. will provide revenues, products and infrastructure that will serve as the European foundation for becoming a trans-Atlantic specialty pharma company with equally important U.S. and EU operations.

OPi (Lyon, France) was a good strategic fit for three primary reasons, according to Bryan Morton, president, CEO and

Read the full 672 word article

How to gain access

Continue reading with a
two-week free trial.